Login to Your Account



Cempra Adds $50.8M to Push Pivotal Solithromycin Program

By Jennifer Boggs
Managing Editor

Friday, June 14, 2013

On Thursday, Cempra Inc. disclosed a successful end-of-Phase II meeting with the FDA, citing only the need for additional funding to proceed with the planned Phase III trial testing I.V.-to-oral administration of macrolide antibiotic solithromycin in CABP.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription